Gossamer Bio Q1 net loss widens to $46.66 million; revenue rises to $16.96 million

• Gossamer Bio posted a net loss of $46.66 million for the quarter ended March 31, 2026, widening from a year earlier as revenue climbed 71.45% to $16.96 million.
• Operating loss widened to $44.87 million as total operating expenses rose 32.38% to $61.82 million.
• Research and development expense increased 13.23% to $43.08 million; general and administrative costs more than doubled to $18.75 million, driven by higher commercial expenses, severance-related personnel costs, stock-based compensation, and professional services.
• Cash, cash equivalents, and marketable securities totaled $99.2 million at March 31, 2026; existing resources are expected to fund operations into first quarter of 2027.
• Company maintained plan to submit a New Drug Application to FDA for seralutinib in pulmonary arterial hypertension in September 2026, while enrollment in the Phase 3 SERANATA study in PH-ILD remains paused following PROSERA results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001728117-26-000032), on May 15, 2026, and is solely responsible for the information contained therein.